Sygnature Discovery Announces Expansion at Alderley Park

Sygnature Discovery is taking a significant stride forward in its ambitious expansion strategy by establishing a cutting-edge facility at Alderley Park in Cheshire.

This strategic expansion marks a pivotal juncture for Sygnature, as it unveils plans to amplify its drug metabolism and pharmacokinetics (DMPK) division, fuelled by an extensive recruitment initiative. The augmented DMPK department, renowned for its ground breaking delivery and analysis of discovery DMPK data to pharmaceutical and biotechnology entities, will seamlessly operate between Sygnature’s Nottingham and Alderley Park sites.

Dr. Jonathan Williams, the Chief Operating Officer, shared insights into this development, stating,

“The demand for our DMPK services and expertise is growing rapidly year on year, so we are expanding the team and bringing in more expertise to meet this growing client need. Following our move into the Discovery Building at BioCity Nottingham in 2017, we have the space to continue to grow the company, but we appreciate that skilled scientists can also be found in other locations. The North West has a wealth of expertise in the field of DMPK and as Alderley Park is home to the UK’s largest life science campus we wanted to align our growth with theirs.”

“To effectively manage our DMPK department across two sites and to retain Sygnature Discovery’s unique culture and values, which have been instrumental to our success, some of the Nottingham-based DMPK team will be relocating to Alderley Park.”

“As a business we have seen significant growth outside of the UK in recent years and we are now focusing heavily on the further expansion of our global client base. Clients come to Sygnature because we are able to offer not only a high quality fully-integrated drug discovery service, but we also have the flexibility to provide DMPK, medicinal chemistry and in vitro biology as stand-alone services.”

Sygnature Discovery’s DMPK division made its debut in January 2015 with the induction of Dr. Tim Schulz-Utermoehl as Director, whose background includes an illustrious tenure at Shire Pharmaceuticals. Under his stewardship, the DMPK department has experienced substantial expansion, marked by the recruitment of specialized scientists and the addition of pioneering capabilities, including recent strides in discovery toxicology.

Elevating the distinction of Sygnature’s DMPK scientists is their remarkable proficiency, with a significant proportion boasting over a decade of experience in their respective domains. This synergy with the comprehensive integrated drug discovery services equips Sygnature Discovery with an unrivalled reputation and an exceptional market positioning.

The forthcoming chapter of growth for Sygnature is nothing short of remarkable, envisioning a twofold augmentation of the DMPK division within the ensuing 18 months, catalysed by the comprehensive recruitment strategy in place.